[Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become...

Area of Science:

• Rheumatology
• Hematology
• Immunology

Context:

• Primary antiphospholipid syndrome (APS) management after thrombotic events typically involves long-term anticoagulation.
• Optimal management for APS patients with stable conditions and decreasing/negative antiphospholipid antibodies (APA) remains unclear.
• This study investigates the outcomes of discontinuing anticoagulation in primary APS patients with persistently negative APA.

Purpose:

• To assess the clinical course of primary APS in patients after cessation of anticoagulation therapy.
• To determine if discontinuing anticoagulation is safe for primary APS patients with persistently negative APA.
• To identify factors influencing the safety of anticoagulation withdrawal in primary APS.

Summary:

• Ten patients with primary APS and a history of thrombosis underwent anticoagulation cessation after achieving persistently negative APA.
• Six patients (60%) maintained negative APA without recurrent thrombosis over a mean follow-up of 21 months.
• Four patients had transient risk factors (pregnancy, immobilization, oral contraceptives) associated with their initial thrombotic event.

Impact:

• Suggests that anticoagulation may be safely discontinued in select primary APS patients with persistent negative APA, particularly those with venous thrombosis and transient risk factors.
• Highlights the potential for de-escalation of therapy in APS management.
• Emphasizes the need for larger studies to validate these findings and refine treatment guidelines.